AAAP Advanced Accelerator Applicatio

36.14
+0.24  (0.67%)
Previous Close 35.90
Open 0.00
Price To book 0.00
Market Cap N/A
Shares 0
Volume 147,440
Short Ratio 0.00
Av. Daily Volume 115,594

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016
Apoptosis
Necrosis
Phase 2 initiated September 2016
Annexin V-128
Apoptosis
Positive opinion by EMA released in October 2016.
Somakit-TOC
Neuroendocrine cancers
PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016.
Lutathera
Inoperable progressive midgut NETs
Approved June 1 2016
Somakit-TATE
Neuroendocrine tumor diagnosis
Ongoing
Annexin V-128
Rheumatoid arthritis and ankylosing spondylitis

Latest News

  1. Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
  2. Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
  3. ETFs with exposure to Advanced Accelerator Applications SA : January 11, 2017
  4. Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA
  5. Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference
  6. Advanced Accelerator Applications downgraded by JMP Securities
  7. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  8. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  9. Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™
  10. Is Advanced Accelerator Application SA (ADR) (AAAP) a Good Stock to Buy?
  11. Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT®
  12. Is Herc Holdings Inc. (HRI) Worthy of Your Portfolio?
  13. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  14. Advanced Accelerator Applications SA :AAAP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  15. Edited Transcript of AAAP earnings conference call or presentation 28-Nov-16 9:30pm GMT
  16. Investor Calendar Invites You to the Advanced Accelerator Applications Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 28, 2016
  17. IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session
  18. Q3 2016 Advanced Accelerator Applications SA Earnings Release - Before Market Open
  19. Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 and Feedback from the FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  20. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3